EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy



Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy



Journal of Clinical Densitometry 9(4): 431-437



Bone mineral density (BMD) is low in men with prostate cancer treated with androgen deprivation therapy (ADT). Intravenous bisphosphonates have been shown to prevent the bone loss, however, the effectiveness of oral bisphosphonates have not been studied in this population. In this retrospective cohort study, we examine the effect of alendronate on BMD in men with prostate cancer receiving ADT. We reviewed the charts of patients receiving ADT referred from the VA Urology Clinic for BMD measurements. Forty seven patients had follow up BMD measurements (17.6+8.3 months). Twenty-two men (47%) were also receiving alendronate 70 mg every week. There was a statistically significant difference (p<0.05) in the percent change of BMD per year at the spine (-1.29+/-0.7% vs. +1.41+/-0.7%), total hip (-0.94+/-0.6% vs. +0.97+/-0.5%), femoral neck (-2.17+/-0.7% vs. +0.32+/-0.6%) and trochanter (-2.01+/-0.7% vs. +0.79+/-0.8%) in the patients not treated compared to those treated with alendronate. In the four other measured sites at the radius (proximal, mid, ultra distal and total), there were no statistically significant differences (p>0.05). These findings confirm that bone loss occurs in men receiving ADT at all sites measured. The use of alendronate prevents bone loss at the spine and hip, but does not seem to have the same protective effect at the radius.

(PDF emailed within 0-6 h: $19.90)

Accession: 048903046

Download citation: RISBibTeXText

PMID: 17097529

DOI: 10.1016/j.jocd.2006.07.005



Related references

Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy. Collegium Antropologicum 29(2): 589-591, 2006

Bone mineral density in prostate cancer patients treated with androgen deprivation therapy; Preliminary results. European Urology Supplements 15(13): E1630-E1631, 2016

Decrease of bone mineral density in Japanese patients with non-metastatic prostate cancer treated with androgen deprivation therapy. Journal of Bone and Mineral Metabolism: -, 2018

Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. Journal of Urology 182(6): 2670-2675, 2009

Androgen deprivation therapy in patients with prostate cancer and changes in bone mineral density. Journal of Bone & Mineral Research 16(Suppl 1): S243, September, 2001

Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer. Infectious Agents and Cancer 6 Suppl 2(): S7-S7, 2011

Influence of androgen deprivation therapy on bone mineral density in men with prostate cancer. Zhonghua Nan Ke Xue 10(10): 761-763, 2004

Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients. Asian Journal of Andrology 6(1): 75-77, 2004

Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocrine-Related Cancer 15(4): 943-952, 2008

Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer. Bju International 103(6): 753-757, 2008

Effect of Diphosphonates on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer. Clinical Genitourinary Cancer: -, 2018

Effect of Androgen-deprivation Therapy on Bone Mineral Density in Japanese Patients with Prostate Cancer. In Vivo 32(2): 409-412, 2018

Predictors of fracture risk and bone mineral density in men with prostate cancer on androgen deprivation therapy. Journal of Osteoporosis 2011: 924595-924595, 2011

Management of decreased bone mineral density (BMD) in men starting androgen deprivation therapy (ADT) for prostate cancer. Journal of Clinical Oncology 26(15_suppl): 16115-16115, 2016

Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology 75(5): 1131-1137, 2010